http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=829

Therapeutic antibodies have become important components of standard care in some areas of clinical practice, but lag behind in others. What can be learned from prior successes and failures of antibody drug development? Interdisciplinary discussions spanning immunobiology, protein engineering, bioprocess development, pharmacokinetics, and clinical medicine for neurological disease, infectious diseases, immunological diseases, and cancer should help identify crosscutting themes and general approaches.

Deadline for Abstracts: Oct. 2, 2006